<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37580807</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1478-6362</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Arthritis research &amp; therapy</Title><ISOAbbreviation>Arthritis Res Ther</ISOAbbreviation></Journal><ArticleTitle>Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study.</ArticleTitle><Pagination><StartPage>148</StartPage><MedlinePgn>148</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">148</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13075-023-03122-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">In addition to decreasing the level of cholesterol, proprotein convertase subtilis kexin 9 (PCSK9) inhibitor has pleiotropic effects, including immune regulation. However, the impact of PCSK9 on autoimmune diseases is controversial. Therefore, we used drug target Mendelian randomization (MR) analysis to investigate the effect of PCSK9 inhibitor on different autoimmune diseases.</AbstractText><AbstractText Label="METHODS">We collected single nucleotide polymorphisms (SNPs) of PCSK9 from published genome-wide association studies statistics and conducted drug target MR analysis to detect the causal relationship between PCSK9 inhibitor and the risk of autoimmune diseases. 3-Hydroxy-3-methylglutaryl-assisted enzyme A reductase (HMGCR) inhibitor, the drug target of statin, was used to compare the effect with that of PCSK9 inhibitor. With the risk of coronary heart disease as a positive control, primary outcomes included the risk of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), myasthenia gravis (MG), multiple sclerosis (MS), asthma, Crohn's disease (CD), ulcerative colitis (UC), and type 1 diabetes (T1D).</AbstractText><AbstractText Label="RESULTS">PCSK9 inhibitor significantly reduced the risk of SLE (OR [95%CI]&#x2009;=&#x2009;0.47 [0.30 to 0.76], p&#x2009;=&#x2009;1.74&#x2009;&#xd7;&#x2009;10<sup>-3</sup>) but increased the risk of asthma (OR [95%CI]&#x2009;=&#x2009;1.15 [1.03 to 1.29], p&#x2009;=&#x2009;1.68&#x2009;&#xd7;&#x2009;10<sup>-2</sup>) and CD (OR [95%CI]&#x2009;=&#x2009;1.38 [1.05 to 1.83], p&#x2009;=&#x2009;2.28&#x2009;&#xd7;&#x2009;10<sup>-2</sup>). In contrast, HMGCR inhibitor increased the risk of RA (OR [95%CI]&#x2009;=&#x2009;1.58 [1.19 to 2.11], p&#x2009;=&#x2009;1.67&#x2009;&#xd7;&#x2009;10<sup>-3</sup>), asthma (OR [95%CI]&#x2009;=&#x2009;1.21 [1.04 to 1.40], p&#x2009;=&#x2009;1.17&#x2009;&#xd7;&#x2009;10<sup>-2</sup>), and CD (OR [95%CI]&#x2009;=&#x2009;1.60 [1.08 to 2.39], p&#x2009;=&#x2009;2.04&#x2009;&#xd7;&#x2009;10<sup>-2</sup>).</AbstractText><AbstractText Label="CONCLUSIONS">PCSK9 inhibitor significantly reduced the risk of SLE but increased the risk of asthma and CD. In contrast, HMGCR inhibitor may be a risk factor for RA, asthma, and CD.</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Xie</LastName><ForeName>Weijia</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Xiangya Hospital, Central South University, 87# Xiangya Road, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Jiaxin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Xiangya Hospital, Central South University, 87# Xiangya Road, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Xiangya Hospital, Central South University, 87# Xiangya Road, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Jian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9154-131X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Xiangya Hospital, Central South University, 87# Xiangya Road, Changsha, Hunan, China. xjian1216@csu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Center for Cerebrovascular Disease of Hunan Province, Central South University, Changsha, Hunan, China. xjian1216@csu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China. xjian1216@csu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arthritis Res Ther</MedlineTA><NlmUniqueID>101154438</NlmUniqueID><ISSNLinking>1478-6354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091362">PCSK9 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057182" MajorTopicYN="N">Mendelian Randomization Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071449" MajorTopicYN="N">Proprotein Convertase 9</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091362" MajorTopicYN="Y">PCSK9 Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001249" MajorTopicYN="Y">Asthma</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune disease</Keyword><Keyword MajorTopicYN="N">Drug-target Mendelian randomization</Keyword><Keyword MajorTopicYN="N">HMGCR</Keyword><Keyword MajorTopicYN="N">Immune regulation</Keyword><Keyword MajorTopicYN="N">PCSK9</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>15</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>23</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37580807</ArticleId><ArticleId IdType="pmc">PMC10424393</ArticleId><ArticleId IdType="doi">10.1186/s13075-023-03122-7</ArticleId><ArticleId IdType="pii">10.1186/s13075-023-03122-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009;33(3&#x2013;4):197&#x2013;207. doi: 10.1016/j.jaut.2009.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2009.09.008</ArticleId><ArticleId IdType="pmc">PMC2783422</ArticleId><ArticleId IdType="pubmed">19819109</ArticleId></ArticleIdList></Reference><Reference><Citation>Durcan L, O&#x2019;Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet (London, England) 2019;393(10188):2332&#x2013;2343. doi: 10.1016/S0140-6736(19)30237-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30237-5</ArticleId><ArticleId IdType="pubmed">31180030</ArticleId></ArticleIdList></Reference><Reference><Citation>Fugger L, Jensen LT, Rossjohn J. Challenges, progress, and prospects of Developing therapies to treat autoimmune diseases. Cell. 2020;181(1):63&#x2013;80. doi: 10.1016/j.cell.2020.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.007</ArticleId><ArticleId IdType="pubmed">32243797</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao KP, Cai T, Gainer VS, Cagan A, Murphy SN, Liu C, et al. Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population. Arthritis Care Res (Hoboken) 2013;65(12):2046&#x2013;2050. doi: 10.1002/acr.22091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22091</ArticleId><ArticleId IdType="pmc">PMC4060244</ArticleId><ArticleId IdType="pubmed">23925980</ArticleId></ArticleIdList></Reference><Reference><Citation>VanEvery H, Yang W, Su J, Olsen N, Bao L, Lu B, et al. Low-density lipoprotein cholesterol and the risk of rheumatoid arthritis: a prospective study in a Chinese cohort. Nutrients. 2022;14(6):1240. doi: 10.3390/nu14061240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14061240</ArticleId><ArticleId IdType="pmc">PMC8954206</ArticleId><ArticleId IdType="pubmed">35334896</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Lopez B, Meza-Meza MR, Parra-Rojas I, Ruiz-Ballesteros AI, Vizmanos-Lamotte B, Munoz-Valle JF, et al. Association of cardiometabolic risk status with clinical activity and damage in systemic lupus erythematosus patients: a cross-sectional study. Clin Immunol. 2021;222:108637. doi: 10.1016/j.clim.2020.108637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108637</ArticleId><ArticleId IdType="pubmed">33232825</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich HN, Gladman DD, Urowitz MB, Bargman JM, Hladunewich MA, Lou W, et al. Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney Int. 2011;79(8):914&#x2013;920. doi: 10.1038/ki.2010.525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2010.525</ArticleId><ArticleId IdType="pubmed">21248713</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikdashi J, Handwerger B, Langenberg P, Miller M, Kittner S. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke. 2007;38(2):281&#x2013;285. doi: 10.1161/01.STR.0000254476.05620.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.0000254476.05620.14</ArticleId><ArticleId IdType="pubmed">17218611</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosoff DB, Bell AS, Jung J, Wagner J, Mavromatis LA, Lohoff FW. Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function. J Am Coll Cardiol. 2022;80(7):653&#x2013;662. doi: 10.1016/j.jacc.2022.05.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.05.041</ArticleId><ArticleId IdType="pubmed">35953131</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu A, Rahman M, Hafstrom I, Ajeganova S, Frostegard J. Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus. Lupus. 2020;29(8):825&#x2013;835. doi: 10.1177/0961203320926253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320926253</ArticleId><ArticleId IdType="pubmed">32479241</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Perez H, Quevedo-Abeledo JC, Tejera-Segura B, de Armas-Rillo L, Rua-Figueroa I, Gonzalez-Gay MA, et al. Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus. Ther Adv Musculoskelet Dis. 2020;12:1759720X20975904. doi: 10.1177/1759720X20975904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1759720X20975904</ArticleId><ArticleId IdType="pmc">PMC7705780</ArticleId><ArticleId IdType="pubmed">33294038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraz-Amaro I, Lopez-Mejias R, Ubilla B, Genre F, Tejera-Segura B, de Vera-Gonzalez AM, et al. Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(6):1013&#x2013;1019.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606890</ArticleId></ArticleIdList></Reference><Reference><Citation>Frostegard J. The role of PCSK9 in inflammation, immunity, and autoimmune diseases. Expert Rev Clin Immunol. 2022;18(1):67&#x2013;74. doi: 10.1080/1744666X.2022.2017281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2022.2017281</ArticleId><ArticleId IdType="pubmed">34928185</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang ZH, Peng J, Ren Z, Yang J, Li TT, Li TH, et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-kappaB pathway. Atherosclerosis. 2017;262:113&#x2013;122. doi: 10.1016/j.atherosclerosis.2017.04.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2017.04.023</ArticleId><ArticleId IdType="pubmed">28535426</ArticleId></ArticleIdList></Reference><Reference><Citation>Punch E, Klein J, Diaba-Nuhoho P, Morawietz H, Garelnabi M. Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis. J Am Heart Assoc. 2022;11(3):e023328. doi: 10.1161/JAHA.121.023328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.121.023328</ArticleId><ArticleId IdType="pmc">PMC9238481</ArticleId><ArticleId IdType="pubmed">35048716</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res. 2017;26(5):2333&#x2013;2355. doi: 10.1177/0962280215597579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280215597579</ArticleId><ArticleId IdType="pmc">PMC5642006</ArticleId><ArticleId IdType="pubmed">26282889</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020;17(3):e1003062. doi: 10.1371/journal.pmed.1003062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003062</ArticleId><ArticleId IdType="pmc">PMC7089422</ArticleId><ArticleId IdType="pubmed">32203549</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274&#x2013;1283. doi: 10.1038/ng.2797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2797</ArticleId><ArticleId IdType="pmc">PMC3838666</ArticleId><ArticleId IdType="pubmed">24097068</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47(10):1121&#x2013;1130. doi: 10.1038/ng.3396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3396</ArticleId><ArticleId IdType="pmc">PMC4589895</ArticleId><ArticleId IdType="pubmed">26343387</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentham J, Morris DL, Graham DSC, Pinder CL, Tombleson P, Behrens TW, et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat Genet. 2015;47(12):1457&#x2013;1464. doi: 10.1038/ng.3434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3434</ArticleId><ArticleId IdType="pmc">PMC4668589</ArticleId><ArticleId IdType="pubmed">26502338</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Saez-Atienzar S, Murphy N, Chio A, Blauwendraat C, International Myasthenia Gravis Genomics C et al. Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proc Natl Acad Sci U S A. 2022;119(5):e2108672119. doi: 10.1073/pnas.2108672119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2108672119</ArticleId><ArticleId IdType="pmc">PMC8812681</ArticleId><ArticleId IdType="pubmed">35074870</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha E, Bae SC, Kim K. Large-scale meta-analysis across East Asian and European populations updated genetic architecture and variant-driven biology of rheumatoid arthritis, identifying 11 novel susceptibility loci. Ann Rheum Dis. 2021;80(5):558&#x2013;565. doi: 10.1136/annrheumdis-2020-219065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-219065</ArticleId><ArticleId IdType="pmc">PMC8053349</ArticleId><ArticleId IdType="pubmed">33310728</ArticleId></ArticleIdList></Reference><Reference><Citation>International Multiple Sclerosis Genetics C. Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45(11):1353&#x2013;1360. doi: 10.1038/ng.2770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2770</ArticleId><ArticleId IdType="pmc">PMC3832895</ArticleId><ArticleId IdType="pubmed">24076602</ArticleId></ArticleIdList></Reference><Reference><Citation>Valette K, Li Z, Bon-Baret V, Chignon A, B&#xe9;rub&#xe9; JC, Eslami A, et al. Prioritization of candidate causal genes for asthma in susceptibility loci derived from UK Biobank. Commun Biol. 2021;4(1):700. doi: 10.1038/s42003-021-02227-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02227-6</ArticleId><ArticleId IdType="pmc">PMC8187656</ArticleId><ArticleId IdType="pubmed">34103634</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet. 2017;49(2):256&#x2013;261. doi: 10.1038/ng.3760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3760</ArticleId><ArticleId IdType="pmc">PMC5289481</ArticleId><ArticleId IdType="pubmed">28067908</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47(9):979&#x2013;986. doi: 10.1038/ng.3359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3359</ArticleId><ArticleId IdType="pmc">PMC4881818</ArticleId><ArticleId IdType="pubmed">26192919</ArticleId></ArticleIdList></Reference><Reference><Citation>Onengut-Gumuscu S, Chen WM, Burren O, Cooper NJ, Quinlan AR, Mychaleckyj JC, et al. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet. 2015;47(4):381&#x2013;386. doi: 10.1038/ng.3245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3245</ArticleId><ArticleId IdType="pmc">PMC4380767</ArticleId><ArticleId IdType="pubmed">25751624</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XF, Xu WJ, Wang FF, Leng R, Yang XK, Ling HZ, et al. Telomere length and development of systemic lupus erythematosus: a Mendelian randomization study. Arthritis Rheumatol (Hoboken, NJ) 2022;74(12):1984&#x2013;1990. doi: 10.1002/art.42304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42304</ArticleId><ArticleId IdType="pubmed">35830513</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408. doi: 10.7554/eLife.34408.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.34408</ArticleId><ArticleId IdType="pmc">PMC5976434</ArticleId><ArticleId IdType="pubmed">29846171</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693&#x2013;698. doi: 10.1038/s41588-018-0099-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0099-7</ArticleId><ArticleId IdType="pmc">PMC6083837</ArticleId><ArticleId IdType="pubmed">29686387</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadimitriou N, Dimou N, Tsilidis KK, Banbury B, Martin RM, Lewis SJ, et al. Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nat Commun. 2020;11(1):597. doi: 10.1038/s41467-020-14389-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-14389-8</ArticleId><ArticleId IdType="pmc">PMC6992637</ArticleId><ArticleId IdType="pubmed">32001714</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackam DG, Hegele RA. Lipid-modifying therapies and stroke prevention. Curr Neurol Neurosci Rep. 2022;22(7):375&#x2013;382. doi: 10.1007/s11910-022-01197-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-022-01197-4</ArticleId><ArticleId IdType="pubmed">35554824</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallego-Colon E, Daum A, Yosefy C. Statins and PCSK9 inhibitors: a new lipid-lowering therapy. Eur J Pharmacol. 2020;878:173114. doi: 10.1016/j.ejphar.2020.173114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173114</ArticleId><ArticleId IdType="pubmed">32302598</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Z, Pothineni NVK, Goel A, Luscher TF, Mehta JL. PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. Cardiovasc Res. 2020;116(5):908&#x2013;915. doi: 10.1093/cvr/cvz313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvz313</ArticleId><ArticleId IdType="pubmed">31746997</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Z, Hu L, Zhang J, Yang W, Liu X, Jia D, et al. PCSK9 (proprotein convertase subtilisin/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36. Circulation. 2021;143(1):45&#x2013;61. doi: 10.1161/CIRCULATIONAHA.120.046290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.046290</ArticleId><ArticleId IdType="pubmed">32988222</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Bao X, Hu M, Chang H, Jiao M, Cheng J, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588(7839):693&#x2013;698. doi: 10.1038/s41586-020-2911-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2911-7</ArticleId><ArticleId IdType="pmc">PMC7770056</ArticleId><ArticleId IdType="pubmed">33177715</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministrini S, Carbone F. PCSK9 and inflammation: their role in autoimmune diseases, with a focus on rheumatoid arthritis and systemic lupus erythematosus. Curr Med Chem. 2022;29(6):970&#x2013;979. doi: 10.2174/0929867328666210810150940.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867328666210810150940</ArticleId><ArticleId IdType="pubmed">34375179</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, et al. An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management. Cureus. 2022;14(10):e30330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9662848</ArticleId><ArticleId IdType="pubmed">36407159</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang C, Luo T, Chen X, Lin L. Elevated level of serum PCSK9 in patients with systemic lupus erythematosus. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2018;34(6):541&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">30236208</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y, Fan S, Tang Y, He M, Ren M, Shi Y, et al. The association between blood lipids and systemic lupus erythematosus: a two-sample Mendelian randomization research. Metabolites. 2022;13(1):27. doi: 10.3390/metabo13010027.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo13010027</ArticleId><ArticleId IdType="pmc">PMC9862633</ArticleId><ArticleId IdType="pubmed">36676952</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Huang S, Lin X, Wen C, He Z, Huang L. The causal relationship between blood lipids and systemic lupus erythematosus risk: a bidirectional two-sample Mendelian randomization study. Front Genet. 2022;13:858653. doi: 10.3389/fgene.2022.858653.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2022.858653</ArticleId><ArticleId IdType="pmc">PMC9043646</ArticleId><ArticleId IdType="pubmed">35495122</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao N, Kong M, Li X, Wei D, Zhu X, Hong Z, et al. Systemic lupus erythematosus and cardiovascular disease: a Mendelian randomization study. Front Immunol. 2022;13:908831. doi: 10.3389/fimmu.2022.908831.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.908831</ArticleId><ArticleId IdType="pmc">PMC9207262</ArticleId><ArticleId IdType="pubmed">35734181</ArticleId></ArticleIdList></Reference><Reference><Citation>Frieri M, Stampfl H. Systemic lupus erythematosus and atherosclerosis: review of the literature. Autoimmun Rev. 2016;15(1):16&#x2013;21. doi: 10.1016/j.autrev.2015.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.08.007</ArticleId><ArticleId IdType="pubmed">26299985</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira CB, Kaplan MJ. Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus. Semin Immunopathol. 2022;44(3):309&#x2013;324. doi: 10.1007/s00281-022-00922-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-022-00922-y</ArticleId><ArticleId IdType="pmc">PMC9064999</ArticleId><ArticleId IdType="pubmed">35355124</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha SB, Rivera AP, Flores Monar GV, Islam H, Puttagunta SM, Islam R, et al. Systemic lupus erythematosus and cardiovascular disease. Cureus. 2022;14(2):e22027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8910778</ArticleId><ArticleId IdType="pubmed">35282557</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2017;76:10&#x2013;20. doi: 10.1016/j.jaut.2016.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2016.10.004</ArticleId><ArticleId IdType="pubmed">27776934</ArticleId></ArticleIdList></Reference><Reference><Citation>Frangou E, Chrysanthopoulou A, Mitsios A, Kambas K, Arelaki S, Angelidou I, et al. REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A) Ann Rheum Dis. 2019;78(2):238&#x2013;248. doi: 10.1136/annrheumdis-2018-213181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-213181</ArticleId><ArticleId IdType="pmc">PMC6352428</ArticleId><ArticleId IdType="pubmed">30563869</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgos PI, Alarcon GS. Thrombosis in systemic lupus erythematosus: risk and protection. Expert Rev Cardiovasc Ther. 2009;7(12):1541&#x2013;1549. doi: 10.1586/erc.09.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erc.09.137</ArticleId><ArticleId IdType="pubmed">19954316</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelegri Y, Cerrato G, Martinuzzo ME, Carreras LO, Forastiero RR. Link between anti-CD36 antibodies and thrombosis in the antiphospholipid syndrome. Clin Exp Rheumatol. 2003;21(2):221&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">12747279</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M, Li W, Harberg C, Chen W, Yue H, Ferreira RB, et al. Cysteine sulfenylation by CD36 signaling promotes arterial thrombosis in dyslipidemia. Blood Adv. 2020;4(18):4494&#x2013;4507. doi: 10.1182/bloodadvances.2020001609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020001609</ArticleId><ArticleId IdType="pmc">PMC7509873</ArticleId><ArticleId IdType="pubmed">32946569</ArticleId></ArticleIdList></Reference><Reference><Citation>Borzini P, Riva M, Nembri P, Rossi E, Pagliaro P, Vergani P, et al. CD36 autoantibodies and thrombotic diathesis, thrombocytopenia and repeated early fetal losses. Vox Sang. 1997;73(1):46&#x2013;48. doi: 10.1159/000461899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000461899</ArticleId><ArticleId IdType="pubmed">9269070</ArticleId></ArticleIdList></Reference><Reference><Citation>Myasoedova E, Crowson CS, Kremers HM, Fitz-Gibbon PD, Therneau TM, Gabriel SE. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis. 2010;69(7):1310&#x2013;1314. doi: 10.1136/ard.2009.122374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2009.122374</ArticleId><ArticleId IdType="pmc">PMC2890039</ArticleId><ArticleId IdType="pubmed">19854708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerekes G, Nurmohamed MT, Gonzalez-Gay MA, Seres I, Paragh G, Kardos Z, et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol. 2014;10(11):691&#x2013;696. doi: 10.1038/nrrheum.2014.121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2014.121</ArticleId><ArticleId IdType="pubmed">25090948</ArticleId></ArticleIdList></Reference><Reference><Citation>Bag-Ozbek A, Giles JT. Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship? Curr Allergy Asthma Rep. 2015;15(2):497. doi: 10.1007/s11882-014-0497-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11882-014-0497-6</ArticleId><ArticleId IdType="pubmed">25504261</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Y, Zheng X, Zhang Z, Geng H, Li X. Circulating PCSK9 relates to aggravated disease activity, Th17/Treg imbalance, and predicts treatment outcome of conventional synthetic DMARDs in rheumatoid arthritis patients. Ir J Med Sci. 2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">36826711</ArticleId></ArticleIdList></Reference><Reference><Citation>Frostegard J, Ahmed S, Hafstrom I, Ajeganova S, Rahman M. Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-alpha: potential underlying mechanisms. Arthritis Res Ther. 2021;23(1):32. doi: 10.1186/s13075-020-02386-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-02386-7</ArticleId><ArticleId IdType="pmc">PMC7814540</ArticleId><ArticleId IdType="pubmed">33461620</ArticleId></ArticleIdList></Reference><Reference><Citation>Soh H, Im JP, Han K, Park S, Hong SW, Moon JM, et al. Crohn&#x2019;s disease and ulcerative colitis are associated with different lipid profile disorders: a nationwide population-based study. Aliment Pharmacol Ther. 2020;51(4):446&#x2013;456. doi: 10.1111/apt.15562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15562</ArticleId><ArticleId IdType="pubmed">31691306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrabovsky V, Zadak Z, Blaha V, Hyspler R, Karlik T, Martinek A, et al. Cholesterol metabolism in active Crohn&#x2019;s disease. Wien Klin Wochenschr. 2009;121(7&#x2013;8):270&#x2013;275. doi: 10.1007/s00508-009-1150-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00508-009-1150-6</ArticleId><ArticleId IdType="pubmed">19562284</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson CP, Lai FY, Nath M, Ye S, Webb TR, Schunkert H, et al. Genetic assessment of potential long-term on-target side effects of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Circ Genom Precis Med. 2019;12(1):e002196. doi: 10.1161/CIRCGEN.118.002196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCGEN.118.002196</ArticleId><ArticleId IdType="pubmed">30645167</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt AF, Hunt NB, Gordillo-Maranon M, Charoen P, Drenos F, Kivimaki M, et al. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nat Commun. 2021;12(1):5640. doi: 10.1038/s41467-021-25703-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25703-3</ArticleId><ArticleId IdType="pmc">PMC8463530</ArticleId><ArticleId IdType="pubmed">34561430</ArticleId></ArticleIdList></Reference><Reference><Citation>Cupido AJ, Reeskamp LF, Hingorani AD, Finan C, Asselbergs FW, Hovingh GK, et al. Joint genetic inhibition of PCSK9 and CETP and the association with coronary artery disease: a factorial Mendelian randomization study. JAMA Cardiol. 2022;7(9):955&#x2013;964. doi: 10.1001/jamacardio.2022.2333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2022.2333</ArticleId><ArticleId IdType="pmc">PMC9350849</ArticleId><ArticleId IdType="pubmed">35921096</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J, Huang Y. Meta-analysis of the association between asthma and serum levels of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol. Ann Allergy Asthma Immunol. 2017;118(1):61&#x2013;65. doi: 10.1016/j.anai.2016.09.447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anai.2016.09.447</ArticleId><ArticleId IdType="pubmed">27839668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko SH, Jeong J, Baeg MK, Han KD, Kim HS, Yoon JS, et al. Lipid profiles in adolescents with and without asthma: Korea National Health and nutrition examination survey data. Lipids Health Dis. 2018;17(1):158. doi: 10.1186/s12944-018-0807-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-018-0807-4</ArticleId><ArticleId IdType="pmc">PMC6052620</ArticleId><ArticleId IdType="pubmed">30021597</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartwright MS, Jeffery DR, Nuss GR, Donofrio PD. Statin-associated exacerbation of myasthenia gravis. Neurology. 2004;63(11):2188. doi: 10.1212/01.WNL.0000145708.03876.C3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000145708.03876.C3</ArticleId><ArticleId IdType="pubmed">15596782</ArticleId></ArticleIdList></Reference><Reference><Citation>Gale J, Danesh-Meyer HV. Statins can induce myasthenia gravis. J Clin Neurosci. 2014;21(2):195&#x2013;197. doi: 10.1016/j.jocn.2013.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2013.11.009</ArticleId><ArticleId IdType="pubmed">24433954</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169&#x2013;180. doi: 10.1056/NEJMra1401483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1401483</ArticleId><ArticleId IdType="pmc">PMC6942519</ArticleId><ArticleId IdType="pubmed">29320652</ArticleId></ArticleIdList></Reference><Reference><Citation>Giubilei F, Antonini G, Di Legge S, Sormani MP, Pantano P, Antonini R, et al. Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurol Scand. 2002;106(2):109&#x2013;112. doi: 10.1034/j.1600-0404.2002.01334.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0404.2002.01334.x</ArticleId><ArticleId IdType="pubmed">12100371</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Bos SD, Harbo HF, Thompson WK, Schork AJ, Bettella F, et al. Genetic overlap between multiple sclerosis and several cardiovascular disease risk factors. Mult Scler. 2016;22(14):1783&#x2013;1793. doi: 10.1177/1352458516635873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458516635873</ArticleId><ArticleId IdType="pmc">PMC5001937</ArticleId><ArticleId IdType="pubmed">26920376</ArticleId></ArticleIdList></Reference><Reference><Citation>Orth M, Bellosta S. Cholesterol: its regulation and role in central nervous system disorders. Cholesterol. 2012;2012:292598. doi: 10.1155/2012/292598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/292598</ArticleId><ArticleId IdType="pmc">PMC3483652</ArticleId><ArticleId IdType="pubmed">23119149</ArticleId></ArticleIdList></Reference><Reference><Citation>Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med. 2003;197(6):725&#x2013;733. doi: 10.1084/jem.20021425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20021425</ArticleId><ArticleId IdType="pmc">PMC2193848</ArticleId><ArticleId IdType="pubmed">12629065</ArticleId></ArticleIdList></Reference><Reference><Citation>Paintlia AS, Paintlia MK, Khan M, Vollmer T, Singh AK, Singh I. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J. 2005;19(11):1407&#x2013;1421. doi: 10.1096/fj.05-3861com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.05-3861com</ArticleId><ArticleId IdType="pubmed">16126908</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigne S, Duc D, Peter B, Rebeaud J, Yersin Y, Ruiz F, et al. Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis. J Neuroinflammation. 2022;19(1):42. doi: 10.1186/s12974-022-02409-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-022-02409-x</ArticleId><ArticleId IdType="pmc">PMC8822860</ArticleId><ArticleId IdType="pubmed">35130916</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>